[PDF][PDF] Why we did what we did: PSMA PET/CT selection criteria for the VISION trial
PH Kuo, T Benson, R Messmann… - Journal of Nuclear …, 2022 - Soc Nuclear Med
After years of development and many published studies, prostate-specific membrane
antigen–targeted radioligand therapy recently reached a critical milestone on March 23 …
antigen–targeted radioligand therapy recently reached a critical milestone on March 23 …
[PDF][PDF] To scan or not to scan: an unnecessary dilemma for PSMA radioligand therapy
S Srinivas, A Iagaru - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
The recently presented and published results of the VISION phase III study of 177Lu-
PSMA617 for metastatic castrationresistant prostate cancer (1) are indeed one of the …
PSMA617 for metastatic castrationresistant prostate cancer (1) are indeed one of the …
[PDF][PDF] 177Lu-PSMA617 and the VISION trial: one of the greatest success stories in the history of nuclear medicine
J Czernin, J Calais - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
The recently published results of the VISION trial (1) represent the culmination of
translational research efforts that started in the 1980s and early 1990s with the discovery of …
translational research efforts that started in the 1980s and early 1990s with the discovery of …
[PDF][PDF] PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy
J Calais, J Czernin - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
Approximately 20% of breast cancers express human epidermal growth factor receptor 2
(Erb-B2 receptor tyrosine kinase 2 [ERBB2], formerly HER2), and 70% express estrogen or …
(Erb-B2 receptor tyrosine kinase 2 [ERBB2], formerly HER2), and 70% express estrogen or …
Seduction by sensitivity: reality, illusion, or delusion? The challenge of assessing outcomes after PSMA imaging selection of patients for treatment
Prostate-specific membrane antigen (PSMA) has long been recognized to be an attractive
target for evaluating prostate cancer (1). Over the past 2 decades, several groups have …
target for evaluating prostate cancer (1). Over the past 2 decades, several groups have …
A VISION substudy of reader agreement on 68Ga-PSMA-11 PET/CT scan interpretation to determine patient eligibility for 177Lu-PSMA-617 radioligand therapy
[68Ga] Ga-PSMA-11 (68Ga-PSMA-11) is used to identify prostate-specific membrane
antigen (PSMA)–positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was …
antigen (PSMA)–positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was …
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Abstract Introduction The Prostate Cancer Foundation (PCF) convened a PCF prostate‐
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …
Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics
Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for
diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has …
diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has …
Why targeting PSMA is a game changer in the management of prostate cancer
NM Donin, RE Reiter - Journal of Nuclear Medicine, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is highly
expressed on prostate adenocarcinomas, exhibits only limited expression in benign and …
expressed on prostate adenocarcinomas, exhibits only limited expression in benign and …
[CITATION][C] Oliver Sartor talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler about FDA approval of PSMA
On December 1, the US Food and Drug Administration (FDA) approved 68Ga-PSMA-11 for
PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with …
PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with …
Related searches
- 177lu psma radioligand therapy
- 177lu psma vision substudy
- vision substudy radioligand therapy
- 177lu psma patient eligibility
- 177lu psma reader agreement
- 177lu psma scan interpretation
- nuclear medicine 177lu psma617
- nuclear medicine success stories
- patient eligibility radioligand therapy
- prostate cancer radioligand therapy
- reader agreement radioligand therapy
- scan interpretation radioligand therapy
- pet imaging psma expression
- 177lu psma therapy eligibility
- 68ga psma radioligand therapy
- 68ga psma vision substudy